Sickle cellis is a horrible disease, but it causes these incredibly painful episodes. Most experimental data we've seen so far seems to point to most people treated having functional cure of the disease at that point. There's also editos medicine working on a disease for a certain form of blindness. It's moving quite slowly and i don't know that, you know, yet we've seen anything superproising.
Genetically edited humans are already here. Gene editing has massive implications for treating chronic illnesses and even the food we eat. So what does this mean for your investments and, y'know, possibly humanity? Ricky Mulvey talks with Motley Fool Advisor Karl Thiel about: - How CRISPR works - Some of the possibilities for CRISPR, from sickle cell cures to drought-resistant crops - How investors can approach investing in gene therapies - Biotech metrics to watch.
Companies mentioned: BLUE, CRSP, GILD, EDIT, VRTX, NTLA
Host: Ricky Mulvey Guest: Karl Theil Engineers: Tim Sparks, Dan Boyd
Learn more about your ad choices. Visit megaphone.fm/adchoices